Aurélien Marabelle

Aurélien Marabelle | JRNLClub

Research Statement

AI generated · 2d ago

Aurélien Marabelle's indexed work centers on immune checkpoint blockade in mismatch repair–deficient and microsatellite instability–high cancers, where his first-author analyses of the KEYNOTE-158 cohorts helped establish tumour mutational burden as a predictive biomarker and supported pembrolizumab's tumour-agnostic approval. His senior-author position paper on managing immune-related dysimmune toxicities became a widely used reference for toxicity grading and treatment, and his reviews on intratumoural administration and tumour-tissue targeting of immunotherapies outline a parallel program of local delivery to convert the tumour itself into an immunization site. Earlier and collaborative contributions include characterizing hyperprogressive disease as a distinct pattern of progression on anti-PD-1/PD-L1 therapy and imaging-based assessment of tumour-infiltrating CD8 cells as a radiomic biomarker of response, alongside a middle-author role in a Cell study of calprotectin and myeloid subsets in severe COVID-19. No software, datasets, patents, or grants are indexed beyond these publications. Across this record, the through-line is a shift from systemic checkpoint blockade toward intratumoural strategies and biomarker-guided patient selection, developed with collaborators such as Alexandra F. Leary and David S. Hong.

Most Cited Works

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Aurelien Marabelle, Dung T Le, Paolo A Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta, Jean-Pierre Delord, Ravit Geva, Maya Gottfried, Nicolas Penel, Aaron R Hansen, Sarina A Piha-Paul, Toshihiko Doi, Bo Gao, Hyun Cheol Chung, Jose Lopez-Martin, Yung-Jue Bang, Ronnie Shapira Frommer, Manisha Shah, Razi Ghori, Andrew K Joe, Scott K Pruitt, Luis A Diaz

Journal of Clinical Oncology2019

3,074Citations

Research Areas

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell ImmunologyMedical Imaging Techniques and ApplicatiOccupational and environmental lung dise

Affiliations & Education

Employment

2014–present· now
Gustave Roussy(FR)

Loading ORCID activity...

Aurélien Marabelle

Sources

Research Statement

Most Cited Works

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Research Areas

Affiliations & Education

Employment

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study